Healthcare Sales & Marketing Network News: Guillain-Barre Syndrome

Searching News Database: Guillain-Barre Syndrome

HSMN NewsFeed - 6 Jul 2022
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Oct 2021
Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jul 2018
FDA Grants Approval of TIBSOVO(R), the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 12 Jan 2018
GSK receives FDA approval for expanded indication for FLUARIX(R) QUADRIVALENT (Influenza Vaccine) for persons 6 months and older
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Nov 2017
Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Biopharmaceuticals Devices Drug Delivery Product Launch

HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch

HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Nov 2016
GSK Receives FDA Approval for Expanded Indication for Flulaval(R) Quadrivalent (Influenza Vaccine) for Infants 6 Months and Older
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Dec 2014
Sanofi Pasteur Announces FDA Approval of Fluzone(R) Intradermal Quadrivalent (Influenza Vaccine) for Adults
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Aug 2014
FDA Approves Use of AFLURIA(R) Influenza Vaccine with PharmaJet’s Needle-Free Injector
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Aug 2013
Additional GlaxoSmithKline quadrivalent intramuscular influenza vaccine approved by FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Jun 2012
PRIMA Study Shows Treatment with Privigen(R) Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals

HSMN NewsFeed - 7 Oct 2010
Privigen(R) Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show
Biopharmaceuticals

HSMN NewsFeed - 21 Apr 2010
Merck Obtains Exclusive Rights to Market and Distribute MassBiologics' Tetanus-Diphtheria (Td) Vaccine in the U.S.
Biopharmaceuticals Licensing Distribution

HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 21 Oct 2008
Abbott's HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology

HSMN NewsFeed - 15 Sep 2008
FDA Grants Approval to Talecris Biotherapeutics for Gamunex(R) as a Treatment for Neurological Disorder CIDP in the United States
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 24 Jun 2008
FDA Approves KINRIX(TM) - New Combination Vaccine for Children
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Feb 2008
Acorda Therapeutics Announces Acquisition of Aminopyridine and Pre-Clinical Assets from Neurorecovery, Inc.
Biopharmaceuticals Acquisitions Neurology

HSMN NewsFeed - 19 Oct 2007
Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Oct 2007
Roche and Trimeris Provide Update on Development of Alternative Administration Options for Delivery of FUZEON(R)
Biopharmaceuticals HIV/AIDS Drug Delivery

HSMN NewsFeed - 28 Sep 2007
CSL Biotherapies announces FDA marketing approval of Afluria(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Sep 2007
FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
Biopharmaceuticals FDA

HSMN NewsFeed - 16 May 2007
FDA Advisory Committee Recommends Expanded Use of FluMist(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Mar 2007
Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 8 Jan 2007
FDA Approves MedImmune's Refrigerated Formulation of FluMist(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Dec 2006
Neurorecovery, Inc. Receives Orphan Drug Designation
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 19 Dec 2006
Neurorecovery, Inc. Updates Clinical Development Program for Guillain-Barré Syndrome (GBS)
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Oct 2006
Roche and Trimeris Provide Update on Development of Needle-Free Administration for FUZEON(R)
Biopharmaceuticals Drug Delivery HIV/AIDS

HSMN NewsFeed - 5 Oct 2006
GSK's New Flu Vaccine, FluLaval(TM), Provides Americans With a New Option for Fighting the Flu
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Oct 2006
New Data Show Unprecedented Undetectable Rates of over 90 Percent in HIV Patients Receiving FUZEON(R) and Investigational Integrase Inhibitor MK-0518
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 18 Jul 2006
MedImmune Receives Complete Response Letter From FDA for New Formulation of FluMist(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Jul 2006
MedImmune Receives FDA Approval to Use Reverse Genetics Technology for FluMist(R) Vaccine Production
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Jun 2006
New Data Show FUZEON(R) Continues to Provide Significant Immune System Benefits in Patients Despite Ongoing Viral Replication
Biopharmaceuticals HIV/AIDS

Return to NewsFeed

Additional items found! 28

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 28 additional stories matching:
Guillain-Barre Syndrome
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!